Literature DB >> 15270903

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

W Jacot, D Bessis, E Jorda, M Ychou, M Fabbro, J-L Pujol, B Guillot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15270903     DOI： 10.1111/j.1365-2133.2004.06026.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  29 in total

Review 1.  Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.

Authors:  Viswanath Reddy Belum; Andrea Cercek; Virginia Sanz-Motilva; Mario E Lacouture
Journal:  Curr Treat Options Oncol       Date:  2013-09

2.  [Cutaneous side effects of EGF-receptor inhibition and their management].

Authors:  R Gutzmer; T Werfel; A Kapp; J Elsner
Journal:  Hautarzt       Date:  2006-06       Impact factor: 0.751

3.  [Acneiform skin eruption in patients with metastatic colorectal carcinoma].

Authors:  K Gethöffer; L-A Schneider; T Peters; L Weber; K Scharffetter-Kochanek
Journal:  Hautarzt       Date:  2006-07       Impact factor: 0.751

4.  Different patterns of toxicity after sequential administration of two anti-EGFR monoclonal antibodies.

Authors:  Miriam López-Gómez; César Gómez-Raposo; María Sereno; Francisco Zambrana; Enrique Casado
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

Review 5.  Molecular therapy in head and neck oncology.

Authors:  Jacques Bernier; Søren M Bentzen; Jan B Vermorken
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

6.  [Cutaneous lesions due to inhibition of epidermal growth factor receptor].

Authors:  E Bierhoff; H W Seifert; T Dirschka
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

Review 7.  Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

Authors:  Jean-Baptiste Bachet; Lucie Peuvrel; Claude Bachmeyer; Ziad Reguiai; Pierre A Gourraud; Olivier Bouché; Marc Ychou; Rene J Bensadoun; Brigitte Dreno; Thierry André
Journal:  Oncologist       Date:  2012-03-16

8.  Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Authors:  Bruno Vincenzi; Daniele Santini; Antonio Russo; Raffaele Addeo; Francesco Giuliani; Liliana Montella; Sergio Rizzo; Olga Venditti; Anna Maria Frezza; Michele Caraglia; Giuseppe Colucci; Salvatore Del Prete; Giuseppe Tonini
Journal:  Oncologist       Date:  2010-01-05

9.  Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; M Vincent
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

10.  Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

Authors:  B Melosky; R Burkes; D Rayson; T Alcindor; N Shear; M Lacouture
Journal:  Curr Oncol       Date:  2009-01       Impact factor: 3.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.